{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:28:04Z","timestamp":1791379684231,"version":"4.3.3"},"reference-count":341,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":915,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["pharmrev.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reviews"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1124\/pharmrev.120.000121","type":"journal-article","created":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T13:55:13Z","timestamp":1655387713000},"page":"552-599","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"title":["The Nitrogen Mustards"],"prefix":"10.1016","volume":"74","author":[{"given":"Martin S.","family":"Highley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Landuyt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Prenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G.","family":"Harper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernst A.","family":"De Bruijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/pharmrev.120.000121_bib1","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1038\/bjc.2013.648","article-title":"A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted solid tumours","volume":"109","author":"Adenis","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1124\/pharmrev.120.000121_bib2","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1093\/annonc\/mds542","article-title":"Efficacy of abbreviated Stanford V chemotherapy and involved-field radiotherapy in early-stage Hodgkin lymphoma: mature results of the G4 trial","volume":"24","author":"Advani","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1124\/pharmrev.120.000121_bib3","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1093\/annonc\/mdq754","article-title":"Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow up on IBCSG Trial IX","volume":"22","author":"Aebi","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1124\/pharmrev.120.000121_bib4","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3389\/fphar.2020.00406","article-title":"Population pharmacokinetic, pharmacogenetic, and pharmacodynamic analysis of cyclophosphamide in Ethiopian breast cancer patients","volume":"11","author":"Ahmed","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1124\/pharmrev.120.000121_bib5","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.clon.2006.11.003","article-title":"Ifosfamide encephalopathy","volume":"19","author":"Ajithkumar","year":"2007","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1124\/pharmrev.120.000121_bib6","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/chir.20662","article-title":"Detection and quantification of (R) and (S)-dechloroethylifosfamide metabolites in plasma from children by enantioselective LC\/MS\/MS","volume":"21","author":"Aleksa","year":"2009","journal-title":"Chirality"},{"key":"10.1124\/pharmrev.120.000121_bib7","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1200\/JCO.2012.43.1817","article-title":"EMA\/CO for high-risk gestational trophoblastic neoplasia: good outcomes with induction low-dose etoposide-cisplatin and genetic analysis","volume":"31","author":"Alifrangis","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1124\/pharmrev.120.000121_bib8","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/sj.leu.2403247","article-title":"Imatinib sensitizes CLL lymphocytes to chlorambucil","volume":"18","author":"Aloyz","year":"2004","journal-title":"Leukemia"},{"key":"10.1124\/pharmrev.120.000121_bib9","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(20)30443-5","article-title":"Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial","volume":"21","author":"Al-Sawaf","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1124\/pharmrev.120.000121_bib10","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1016\/j.clbc.2017.08.013","article-title":"Phase I trial of veliparib, a poly ADP ribose polymerase inhibitor, plus metronomic cyclophosphamide in metastatic HER2-negative breast cancer","volume":"18","author":"Anampa","year":"2018","journal-title":"Clin Breast Cancer"},{"key":"10.1124\/pharmrev.120.000121_bib11","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1016\/j.ejca.2011.05.030","article-title":"Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand?","volume":"47","author":"Anninga","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1124\/pharmrev.120.000121_bib12","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1158\/2326-6066.CIR-17-0356","article-title":"Robust antitumor responses result from local chemotherapy and CTLA-4 blockade","volume":"6","author":"Ariyan","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"10.1124\/pharmrev.120.000121_bib13","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/pbc.21093","article-title":"Comparison of results of a pilot study of alternating vincristine\/doxorubicin\/cyclophosphamide and etoposide\/ifosfamide with IRS-IV in intermediate risk rhabdomyosarcoma: a report from the Children\u2019s Oncology Group","volume":"50","author":"Arndt","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"10.1124\/pharmrev.120.000121_bib14","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/BF00638623","article-title":"Nemartige Krebs - Chemotherapeutika ans der Gruppe der Zyklischen-N-lost-phosphamidester","volume":"45","author":"Arnold","year":"1958","journal-title":"Naturwissenschaften"},{"key":"10.1124\/pharmrev.120.000121_bib15","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s10067-020-05276-0","article-title":"Influence of glutathione S transferase A1 gene polymorphism (-69C\u2009>\u2009T, rs3957356) on intravenous cyclophosphamide efficacy and side effects: a case-control study in Egyptian patients with lupus nephritis","volume":"40","author":"Attia","year":"2021","journal-title":"Clin Rheumatol"},{"key":"10.1124\/pharmrev.120.000121_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151696","article-title":"Glutathione S transferases polymorphisms are independent prognostic factors in lupus nephritis treated with cyclophosphamide","volume":"11","author":"Audemard-Verger","year":"2016","journal-title":"PLoS One"},{"key":"10.1124\/pharmrev.120.000121_bib17","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3324\/haematol.2017.181339","article-title":"Melphalan 140 mg\/m2 or 200 mg\/m2 for autologous transplantation in myeloma: results from the Collaboration to collect autologous transplant outcomes in lymphoma and myeloma (CALM) study. A report by the EBMT chronic malignancies working party","volume":"103","author":"Auner","year":"2018","journal-title":"Haematologica"},{"key":"10.1124\/pharmrev.120.000121_bib18","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1200\/JCO.1992.10.6.995","article-title":"Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response","volume":"10","author":"Ayash","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1124\/pharmrev.120.000121_bib19","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s00467-011-1830-0","article-title":"Cyclophosphamide in steroid-dependent nephrotic syndrome","volume":"26","author":"Azib","year":"2011","journal-title":"Pediatr Nephrol"},{"key":"10.1124\/pharmrev.120.000121_bib20","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/ajh.24415","article-title":"Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia","volume":"91","author":"Badar","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1124\/pharmrev.120.000121_bib21","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/j.jchromb.2009.04.025","article-title":"Simultaneous determination of cyclophosphamide and carboxyethylphosphoramide mustard in human plasma using online extraction and electrospray tandem mass spectrometry (HTLC-ESI-MS\/MS)","volume":"877","author":"Bai","year":"2009","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1124\/pharmrev.120.000121_bib22","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/bmt.2011.254","article-title":"Population pharmacokinetics of cyclophosphamide in patients with thalassemia major undergoing HSCT","volume":"47","author":"Balasubramanian","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1124\/pharmrev.120.000121_bib23","first-page":"CD010908","article-title":"Cyclophosphamide for connective tissue disease-associated interstitial lung disease","volume":"1","author":"Barnes","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1124\/pharmrev.120.000121_bib24","doi-asserted-by":"crossref","first-page":"272","DOI":"10.3390\/ph14030272","article-title":"Pharmacokinetics and pharmacogenetics of cyclophosphamide in a neonate and infant childhood cancer patient population","volume":"14","author":"Barnett","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1124\/pharmrev.120.000121_bib25","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/bjc.1998.34","article-title":"Multidrug resistance protein-mediated transport of chlorambucil and melphalan conjugated to glutathione","volume":"77","author":"Barnouin","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1124\/pharmrev.120.000121_bib26","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/1476-4598-12-103","article-title":"Oncolytic viruses as therapeutic cancer vaccines","volume":"12","author":"Bartlett","year":"2013","journal-title":"Mol Cancer"},{"key":"10.1124\/pharmrev.120.000121_bib27","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1159\/000113017","article-title":"A phase II study of cisplatin, ifosfamide and epirubicin combination chemotherapy in adults with nonmetastatic and extremity osteosarcomas","volume":"72","author":"Basaran","year":"2007","journal-title":"Oncology"},{"key":"10.1124\/pharmrev.120.000121_bib28","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0378-4347(99)00178-4","article-title":"Determination of cyclophosphamide and its metabolites in human plasma by high-performance liquid chromatography-mass spectrometry","volume":"729","author":"Baumann","year":"1999","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"10.1124\/pharmrev.120.000121_bib29","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.bbmt.2012.08.011","article-title":"Fifty years of melphalan use in hematopoietic stem cell transplantation","volume":"19","author":"Bayraktar","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1124\/pharmrev.120.000121_bib30","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/bjc.2014.563","article-title":"Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer","volume":"112","author":"Bazzola","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1124\/pharmrev.120.000121_bib31","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1245\/s10434-012-2373-8","article-title":"A phase I multi-institutional study of systemic sorafenib in conjunction with regional melphalan for in-transit melanoma of the extremity","volume":"19","author":"Beasley","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"10.1124\/pharmrev.120.000121_bib32","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1200\/JCO.2010.32.1224","article-title":"Prospective multicenter phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with advanced extremity melanoma","volume":"29","author":"Beasley","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1124\/pharmrev.120.000121_bib33","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.athoracsur.2019.02.071","article-title":"Multicenter phase II clinical trial of isolated lung perfusion in patients with lung metastases","volume":"108","author":"Beckers","year":"2019","journal-title":"Ann Thorac Surg"},{"key":"10.1124\/pharmrev.120.000121_bib34","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1002\/cncr.24368","article-title":"Phase 2 trial of two courses of cyclophosphamide and etoposide for relapsed high-risk osteosarcoma patients","volume":"115","author":"Berger","year":"2009","journal-title":"Cancer"},{"key":"10.1124\/pharmrev.120.000121_bib35","first-page":"4342","article-title":"Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells","volume":"63","author":"Bertolini","year":"2003","journal-title":"Cancer Res"},{"issue":"Suppl 135","key":"10.1124\/pharmrev.120.000121_bib36","doi-asserted-by":"crossref","first-page":"S203","DOI":"10.1016\/j.bbmt.2010.12.157","article-title":"Cardiomyopathy following high dose melphalan conditioning prior to autologous peripheral blood stem cell transplantation for multiple myeloma and primary amyloidosis (Abstract)","volume":"17","author":"Bleeker","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1124\/pharmrev.120.000121_bib37","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1600-0609.2011.01634.x","article-title":"Melphalan 100 mg\/m2 with stem cell support as first relapse treatment is safe and effective for myeloma patients with long remission after autologous stem cell transplantation","volume":"87","author":"Blimark","year":"2011","journal-title":"Eur J Haematol"},{"key":"10.1124\/pharmrev.120.000121_bib38","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/nrclinonc.2016.64","article-title":"Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect","volume":"13","author":"Bocci","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1124\/pharmrev.120.000121_bib39","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1056\/NEJM199504063321401","article-title":"Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up","volume":"332","author":"Bonadonna","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.120.000121_bib40","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/jso.24984","article-title":"Hepatic artery infusion of melphalan in patients with liver metastases from ocular melanoma","volume":"117","author":"Boone","year":"2018","journal-title":"J Surg Oncol"},{"key":"10.1124\/pharmrev.120.000121_bib41","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1207842","article-title":"mRNA-transfected dendritic cell vaccine in combination with metronomic cyclophosphamide as treatment for patients with advanced malignant melanoma","volume":"5","author":"Borch","year":"2016","journal-title":"OncoImmunology"},{"key":"10.1124\/pharmrev.120.000121_bib42","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1158\/1078-0432.CCR-06-1209","article-title":"Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration","volume":"13","author":"Bracci","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1124\/pharmrev.120.000121_bib43","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/j.fertnstert.2013.07.002","article-title":"Multidrug-resistant transport activity protects oocytes from chemotherapeutic agents and changes during oocyte maturation","volume":"100","author":"Brayboy","year":"2013","journal-title":"Fertil Steril"},{"key":"10.1124\/pharmrev.120.000121_bib44","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1158\/1078-0432.CCR-04-0155","article-title":"Phase I study of MetXia-P450 gene therapy and oral cyclophosphamide for patients with advanced breast cancer or melanoma","volume":"11","author":"Braybrooke","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1124\/pharmrev.120.000121_bib45","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1182\/blood-2014-03-563759","article-title":"Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study","volume":"124","author":"Bringhen","year":"2014","journal-title":"Blood"},{"key":"10.1124\/pharmrev.120.000121_bib46","doi-asserted-by":"crossref","first-page":"376","DOI":"10.5414\/CPP40376","article-title":"New insights into the clinical pharmacokinetics of trofosfamide","volume":"40","author":"Brinker","year":"2002","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"Suppl A","key":"10.1124\/pharmrev.120.000121_bib47","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0305-7372(83)80002-4","article-title":"The oxazaphosphorines","volume":"10","author":"Brock","year":"1983","journal-title":"Cancer Treat Rev"},{"key":"10.1124\/pharmrev.120.000121_bib48","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s12026-009-8149-y","article-title":"High-dose cyclophosphamide for autoimmunity and alloimmunity","volume":"47","author":"Brodsky","year":"2010","journal-title":"Immunol Res"},{"key":"10.1124\/pharmrev.120.000121_bib49","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.7326\/0003-4819-129-12-199812150-00007","article-title":"Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease","volume":"129","author":"Brodsky","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1124\/pharmrev.120.000121_bib50","doi-asserted-by":"crossref","first-page":"5172","DOI":"10.1039\/C9AN00576E","article-title":"A high-specificity immunoassay for the therapeutic drug monitoring of cyclophosphamide","volume":"144","author":"Broto","year":"2019","journal-title":"Analyst (Lond)"},{"key":"10.1124\/pharmrev.120.000121_bib51","first-page":"1878","article-title":"Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer","volume":"60","author":"Browder","year":"2000","journal-title":"Cancer Res"},{"key":"10.1124\/pharmrev.120.000121_bib52","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00280-005-0061-0","article-title":"Chloroacetaldehyde: mode of antitumor action of the ifosfamide metabolite","volume":"57","author":"Br\u00fcggemann","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/pharmrev.120.000121_bib53","doi-asserted-by":"crossref","first-page":"5190","DOI":"10.1158\/1078-0432.CCR-06-0474","article-title":"High-dose celecoxib and metronomic \u201clow-dose\u201d cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin\u2019s lymphoma","volume":"12","author":"Buckstein","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1124\/pharmrev.120.000121_bib54","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jama.2018.18743","article-title":"Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis: a randomized clinical trial","volume":"321","author":"Burt","year":"2019","journal-title":"JAMA"},{"key":"10.1124\/pharmrev.120.000121_bib55","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1200\/JCO.1997.15.5.1885","article-title":"Dose escalation of cyclophosphamide in patients with breast cancer: consequences for pharmacokinetics and metabolism","volume":"15","author":"Busse","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1124\/pharmrev.120.000121_bib56","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1124\/dmd.115.063628","article-title":"Hydroxylation and N-dechloroethylation of Ifosfamide and deuterated Ifosfamide by the human cytochrome p450s and their commonly occurring polymorphisms","volume":"43","author":"Calinski","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pharmrev.120.000121_bib57","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s00262-013-1397-7","article-title":"Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response","volume":"62","author":"Camisaschi","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"10.1124\/pharmrev.120.000121_bib58","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1158\/1078-0432.CCR-19-2685","article-title":"Exposure-toxicity association of cyclophosphamide and its metabolites in infants and young children with primary brain tumors: implications for dosing","volume":"26","author":"Campagne","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"Suppl 1","key":"10.1124\/pharmrev.120.000121_bib59","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.clml.2011.02.006","article-title":"Chlorambucil--still not bad: a reappraisal","volume":"11","author":"Catovsky","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1124\/pharmrev.120.000121_bib60","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(07)61125-8","article-title":"Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial","volume":"370","author":"Catovsky","year":"2007","journal-title":"Lancet"},{"key":"10.1124\/pharmrev.120.000121_bib61","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1038\/mt.2011.113","article-title":"Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus","volume":"19","author":"Cerullo","year":"2011","journal-title":"Mol Ther"},{"key":"10.1124\/pharmrev.120.000121_bib62","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/bjh.16095","article-title":"Frontline treatment of elderly non transplant-eligible multiple myeloma patients using CyBorD with or without thalidomide-based consolidation: a retrospective multi-centre analysis of real-world data","volume":"187","author":"Chan","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1124\/pharmrev.120.000121_bib63","first-page":"6421","article-title":"Clinical pharmacokinetics of cyclophosphamide and metabolites with and without SR-2508","volume":"54","author":"Chan","year":"1994","journal-title":"Cancer Res"},{"key":"10.1124\/pharmrev.120.000121_bib64","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/S0022-3565(24)29242-9","article-title":"Insights into the mechanisms of ifosfamide encephalopathy: drug metabolites have agonistic effects on \u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)\/kainate receptors and induce cellular acidification in mouse cortical neurons","volume":"299","author":"Chatton","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.120.000121_bib65","doi-asserted-by":"crossref","first-page":"766","DOI":"10.3109\/10428194.2015.1099647","article-title":"Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an update","volume":"57","author":"Cheson","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1124\/pharmrev.120.000121_bib66","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.ejca.2011.03.008","article-title":"Pharmacokinetics of cyclophosphamide and its metabolites in paediatric patients receiving high-dose myeloablative therapy","volume":"47","author":"Chinnaswamy","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1124\/pharmrev.120.000121_bib67","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/COC.0b013e3181979204","article-title":"A phase 2 trial of glufosfamide in combination with gemcitabine in chemotherapy-naive pancreatic adenocarcinoma","volume":"33","author":"Chiorean","year":"2010","journal-title":"Am J Clin Oncol"},{"key":"10.1124\/pharmrev.120.000121_bib68","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/cpt.644","article-title":"Associations of high-dose melphalan pharmacokinetics and outcomes in the setting of a randomized cryotherapy trial","volume":"102","author":"Cho","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pharmrev.120.000121_bib69","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.eururo.2008.05.007","article-title":"Intravesical botulinum toxin A administration inhibits COX-2 and EP4 expression and suppresses bladder hyperactivity in cyclophosphamide-induced cystitis in rats","volume":"56","author":"Chuang","year":"2009","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.120.000121_bib70","doi-asserted-by":"crossref","first-page":"4206","DOI":"10.1074\/jbc.M109.040444","article-title":"Endogenous nerve growth factor regulates collagen expression and bladder hypertrophy through Akt and MAPK pathways during cystitis","volume":"285","author":"Chung","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1124\/pharmrev.120.000121_bib71","doi-asserted-by":"crossref","first-page":"9616","DOI":"10.1038\/s41598-019-46025-x","article-title":"Dysfunctional MDR-1 disrupts mitochondrial homeostasis in the oocyte and ovary","volume":"9","author":"Clark","year":"2019","journal-title":"Sci Rep"},{"key":"10.1124\/pharmrev.120.000121_bib72","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1002\/acr.20605","article-title":"Ovarian reserve diminished by oral cyclophosphamide therapy for granulomatosis with polyangiitis (Wegener\u2019s)","volume":"63","author":"Clowse","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1124\/pharmrev.120.000121_bib73","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/00000658-195810000-00009","article-title":"Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit","volume":"148","author":"Creech","year":"1958","journal-title":"Ann Surg"},{"key":"10.1124\/pharmrev.120.000121_bib74","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1200\/JCO.2001.19.12.3091","article-title":"Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease","volume":"19","author":"Crist","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1124\/pharmrev.120.000121_bib75","first-page":"5029","article-title":"Cytotoxicity, DNA cross-linking, and single strand breaks induced by activated cyclophosphamide and acrolein in human leukemia cells","volume":"46","author":"Crook","year":"1986","journal-title":"Cancer Res"},{"key":"10.1124\/pharmrev.120.000121_bib76","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.coi.2008.04.008","article-title":"Regulatory T cells and treatment of cancer","volume":"20","author":"Curiel","year":"2008","journal-title":"Curr Opin Immunol"},{"key":"10.1124\/pharmrev.120.000121_bib77","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.immuni.2016.09.009","article-title":"Enterococcus hirae and Barnesiella intestinihominis facilitate cyclophosphamide-induced therapeutic immunomodulatory effects","volume":"45","author":"Daill\u00e8re","year":"2016","journal-title":"Immunity"},{"key":"10.1124\/pharmrev.120.000121_bib78","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/jhrc.1240201215","article-title":"Determination of melphalan and hydrolysis products in body fluids by GC-MS","volume":"20","author":"de Boeck","year":"1997","journal-title":"J High Resolut Chromatogr"},{"key":"10.1124\/pharmrev.120.000121_bib79","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jchromb.2014.09.008","article-title":"Analysis of cyclophosphamide and carboxyethylphosphoramide mustard enantiomers in human plasma and application to clinical pharmacokinetics","volume":"971","author":"de Castro","year":"2014","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1124\/pharmrev.120.000121_bib80","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jchromb.2015.12.049","article-title":"Enantioselective analysis of 4-hydroxycyclophosphamide in human plasma with application to a clinical pharmacokinetic study","volume":"1011","author":"de Castro","year":"2016","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1124\/pharmrev.120.000121_bib81","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/CAD.0b013e3280109411","article-title":"Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogenetics","volume":"18","author":"Deeken","year":"2007","journal-title":"Anticancer Drugs"},{"key":"10.1124\/pharmrev.120.000121_bib82","doi-asserted-by":"crossref","first-page":"4899","DOI":"10.1200\/JCO.2008.17.4789","article-title":"Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer","volume":"26","author":"Dellapasqua","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1124\/pharmrev.120.000121_bib83","doi-asserted-by":"crossref","first-page":"4036","DOI":"10.1200\/JCO.2011.35.6618","article-title":"Long-term results of tumor necrosis factor \u03b1- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas","volume":"29","author":"Deroose","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1124\/pharmrev.120.000121_bib84","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1158\/1078-0432.CCR-10-2227","article-title":"Frequency of circulating Tregs with demethylated FOXP3 intron 1 in melanoma patients receiving tumor vaccines and potentially Treg-depleting agents","volume":"17","author":"de Vries","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1124\/pharmrev.120.000121_bib85","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1054\/bjoc.1999.1032","article-title":"Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion","volume":"82","author":"de Wilt","year":"2000","journal-title":"Br J Cancer"},{"key":"10.1124\/pharmrev.120.000121_bib86","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1093\/neuonc\/not321","article-title":"Consequences of cancer treatments on adult hippocampal neurogenesis: implications for cognitive function and depressive symptoms","volume":"16","author":"Dias","year":"2014","journal-title":"Neuro-oncol"},{"key":"10.1124\/pharmrev.120.000121_bib87","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1080\/15592294.2019.1631111","article-title":"Pre-conceptional maternal exposure to cyclophosphamide results in modifications of DNA methylation in F1 and F2 mouse oocytes: evidence for transgenerational effects","volume":"14","author":"Di Emidio","year":"2019","journal-title":"Epigenetics"},{"key":"10.1124\/pharmrev.120.000121_bib88","doi-asserted-by":"crossref","first-page":"15021","DOI":"10.1038\/nrdp.2015.21","article-title":"Retinoblastoma","volume":"1","author":"Dimaras","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"10.1124\/pharmrev.120.000121_bib89","doi-asserted-by":"crossref","first-page":"3614","DOI":"10.1002\/eji.201444879","article-title":"Human regulatory T cells lack the cyclophosphamide-extruding transporter ABCB1 and are more susceptible to cyclophosphamide-induced apoptosis","volume":"44","author":"Dimeloe","year":"2014","journal-title":"Eur J Immunol"},{"key":"10.1124\/pharmrev.120.000121_bib90","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.ygyno.2017.05.013","article-title":"Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial","volume":"146","author":"Dinkic","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"Suppl 5, P-132","key":"10.1124\/pharmrev.120.000121_bib91","doi-asserted-by":"crossref","first-page":"v36","DOI":"10.1093\/annonc\/mdy151.131","article-title":"Poly-ligand profiling differentiates pancreatic cancer patients according to treatment benefit from gemcitabine+placebo versus gemcitabine+evofosfamide and identifies candidate targets (Abstract)","volume":"29","author":"Domenyuk","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1124\/pharmrev.120.000121_bib92","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/bph.12467","article-title":"Role of CXCR2 and TRPV1 in functional, inflammatory and behavioural changes in the rat model of cyclophosphamide-induced haemorrhagic cystitis","volume":"171","author":"Dornelles","year":"2014","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pharmrev.120.000121_bib93","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/fcp.12345","article-title":"Possible role of CYP2B6 genetic polymorphisms in ifosfamide-induced encephalopathy: report of three cases","volume":"32","author":"Duflot","year":"2018","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1124\/pharmrev.120.000121_bib94","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1002\/cncr.24969","article-title":"Cyclophosphamide, methotrexate, and fluorouracil; oral cyclophosphamide; levamisole; or no adjuvant therapy for patients with high-risk, premenopausal breast cancer","volume":"116","author":"Ejlertsen","year":"2010","journal-title":"Cancer"},{"key":"10.1124\/pharmrev.120.000121_bib95","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/FPC.0b013e3282fc9766","article-title":"Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide","volume":"18","author":"Ekhart","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"10.1124\/pharmrev.120.000121_bib96","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jchromb.2007.04.024","article-title":"Simultaneous quantification of cyclophosphamide and its active metabolite 4-hydroxycyclophosphamide in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry (LC-MS\/MS)","volume":"854","author":"Ekhart","year":"2007","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1124\/pharmrev.120.000121_bib97","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1097\/FPC.0b013e328313aaa4","article-title":"Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin","volume":"18","author":"Ekhart","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"10.1124\/pharmrev.120.000121_bib98","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0141979","article-title":"Cytochrome P450 oxidoreductase influences CYP2B6 activity in cyclophosphamide bioactivation","volume":"10","author":"El-Serafi","year":"2015","journal-title":"PLoS One"},{"key":"10.1124\/pharmrev.120.000121_bib99","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1084\/jem.20042167","article-title":"Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response","volume":"201","author":"Ercolini","year":"2005","journal-title":"J Exp Med"},{"key":"10.1124\/pharmrev.120.000121_bib100","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s11739-019-02035-1","article-title":"Update on the treatment of Beh\u00e7et\u2019s syndrome","volume":"14","author":"Esatoglu","year":"2019","journal-title":"Intern Emerg Med"},{"key":"10.1124\/pharmrev.120.000121_bib101","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1124\/pharmrev.120.000121_bib102","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/j.ejca.2012.03.009","article-title":"Long term renal toxicity of ifosfamide in adult patients--5 year data","volume":"48","author":"Farry","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1124\/pharmrev.120.000121_bib103","first-page":"100","article-title":"Malignancies in Wegener\u2019s granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients","volume":"35","author":"Faurschou","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1124\/pharmrev.120.000121_bib104","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ejca.2020.03.010","article-title":"Phase I expansion cohort to evaluate the combination of bevacizumab, sorafenib and low-dose cyclophosphamide in children and young adults with refractory or recurrent solid tumours","volume":"132","author":"Federico","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1124\/pharmrev.120.000121_bib105","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1200\/JCO.2009.25.1561","article-title":"TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis","volume":"28","author":"Feldman","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1124\/pharmrev.120.000121_bib106","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/clc.20904","article-title":"Melphalan-induced supraventricular tachycardia: incidence and risk factors","volume":"34","author":"Feliz","year":"2011","journal-title":"Clin Cardiol"},{"key":"10.1124\/pharmrev.120.000121_bib107","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1200\/JCO.2011.38.4420","article-title":"Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG\/OS-1","volume":"30","author":"Ferrari","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1124\/pharmrev.120.000121_bib108","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","article-title":"Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial","volume":"127","author":"Fischer","year":"2016","journal-title":"Blood"},{"key":"10.1124\/pharmrev.120.000121_bib109","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1200\/JCO.18.00605","article-title":"First-line treatment of patients with indolent Non-Hodgkin lymphoma or mantel-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study","volume":"37","author":"Flinn","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1124\/pharmrev.120.000121_bib110","doi-asserted-by":"crossref","first-page":"34009","DOI":"10.18632\/oncotarget.26131","article-title":"Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients","volume":"9","author":"Franssen","year":"2018","journal-title":"Oncotarget"},{"issue":"Suppl 2","key":"10.1124\/pharmrev.120.000121_bib111","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1159\/000073366","article-title":"Ifosfamide in the adjuvant therapy of soft tissue sarcomas","volume":"65","author":"Frustaci","year":"2003","journal-title":"Oncology"},{"key":"10.1124\/pharmrev.120.000121_bib112","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1200\/JCO.2007.12.1939","article-title":"Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia","volume":"26","author":"Garcia","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1124\/pharmrev.120.000121_bib113","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/s10637-018-0583-z","article-title":"Phase II trial of ifosfamide in combination with the VEGFR inhibitor sorafenib in advanced soft tissue sarcoma: a Spanish group for research on sarcomas (GEIS) study","volume":"36","author":"Garc\u00eda Del Muro","year":"2018","journal-title":"Invest New Drugs"},{"key":"10.1124\/pharmrev.120.000121_bib114","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2017.09.036","article-title":"Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006\/sarcome-09 study","volume":"88","author":"Gaspar","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1124\/pharmrev.120.000121_bib115","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0959-8049(96)00439-X","article-title":"Ifosfamide and etoposide in childhood osteosarcoma. A phase II study of the French Society of Paediatric Oncology","volume":"33","author":"Gentet","year":"1997","journal-title":"Eur J Cancer"},{"key":"10.1124\/pharmrev.120.000121_bib116","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/ajh.23472","article-title":"Waldenstr\u00f6m macroglobulinemia: 2013 update on diagnosis, risk stratification, and management","volume":"88","author":"Gertz","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1124\/pharmrev.120.000121_bib117","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41408-018-0080-9","article-title":"Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018","volume":"8","author":"Gertz","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1124\/pharmrev.120.000121_bib118","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1002\/cncr.30051","article-title":"Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin light-chain amyloidosis","volume":"122","author":"Gertz","year":"2016","journal-title":"Cancer"},{"key":"10.1124\/pharmrev.120.000121_bib119","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/eji.200324181","article-title":"CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative","volume":"34","author":"Ghiringhelli","year":"2004","journal-title":"Eur J Immunol"},{"key":"10.1124\/pharmrev.120.000121_bib120","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00262-006-0225-8","article-title":"Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients","volume":"56","author":"Ghiringhelli","year":"2007","journal-title":"Cancer Immunol Immunother"},{"key":"10.1124\/pharmrev.120.000121_bib121","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.bbmt.2014.03.022","article-title":"A single nucleotide polymorphism in SLC7A5 is associated with gastrointestinal toxicity after high-dose melphalan and autologous stem cell transplantation for multiple myeloma","volume":"20","author":"Giglia","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1124\/pharmrev.120.000121_bib122","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/BF00686153","article-title":"Determination of the urinary excretion of ifosfamide and its phosphorated metabolites by phosphorus-31 nuclear magnetic resonance spectroscopy","volume":"31","author":"Gilard","year":"1993","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/pharmrev.120.000121_bib123","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1200\/JCO.2012.41.9416","article-title":"Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma","volume":"30","author":"Gisselbrecht","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1124\/pharmrev.120.000121_bib124","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/leu.2015.14","article-title":"Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study","volume":"29","author":"Goede","year":"2015","journal-title":"Leukemia"},{"key":"10.1124\/pharmrev.120.000121_bib125","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1182\/blood.V68.5.1114.1114","article-title":"Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor","volume":"68","author":"Goldberg","year":"1986","journal-title":"Blood"},{"key":"10.1124\/pharmrev.120.000121_bib126","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000024423","article-title":"Evaluating the role of GSTP1 genetic polymorphism (rs1695, 313A>G) as a predictor in cyclophosphamide-induced toxicities","volume":"100","author":"Gong","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"10.1124\/pharmrev.120.000121_bib127","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1001\/jama.1946.02870380008004","article-title":"Nitrogen mustard therapy; use of methyl-bis (beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for Hodgkin\u2019s disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders","volume":"132","author":"Goodman","year":"1946","journal-title":"J Am Med Assoc"},{"key":"10.1124\/pharmrev.120.000121_bib128","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1200\/JCO.2002.20.2.426","article-title":"Phase II\/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial","volume":"20","author":"Goorin","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1124\/pharmrev.120.000121_bib129","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/S0959-8049(01)00083-1","article-title":"A randomised phase II study on neo-adjuvant chemotherapy for \u2018high-risk\u2019 adult soft-tissue sarcoma","volume":"37","author":"Gortzak","year":"2001","journal-title":"Eur J Cancer"},{"key":"10.1124\/pharmrev.120.000121_bib130","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1093\/annonc\/mdh431","article-title":"Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma","volume":"15","author":"Grobmyer","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1124\/pharmrev.120.000121_bib131","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/S1470-2045(17)30334-0","article-title":"Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial","volume":"18","author":"Gronchi","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1124\/pharmrev.120.000121_bib132","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1186\/s13104-017-2738-y","article-title":"Surgical versus percutaneous isolated pelvic perfusion (IPP) for advanced melanoma: comparison in terms of melphalan pharmacokinetic pelvic bio-availability","volume":"10","author":"Guadagni","year":"2017","journal-title":"BMC Res Notes"},{"key":"10.1124\/pharmrev.120.000121_bib133","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1182\/blood-2014-02-514778","article-title":"Conditioning regimens for hematopoietic cell transplantation: one size does not fit all","volume":"124","author":"Gyurkocza","year":"2014","journal-title":"Blood"},{"key":"10.1124\/pharmrev.120.000121_bib134","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/acr.21664","article-title":"American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis","volume":"64","author":"Hahn","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1124\/pharmrev.120.000121_bib135","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.3390\/molecules25071542","article-title":"Genetic polymorphism of GSTP-1 affects cyclophosphamide treatment of autoimmune diseases","volume":"25","author":"Hajdin\u00e1k","year":"2020","journal-title":"Molecules"},{"key":"10.1124\/pharmrev.120.000121_bib136","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jchromb.2018.04.016","article-title":"A sensitive and rapid ultra high-performance liquid chromatography with tandem mass spectrometric assay for the simultaneous quantitation of cyclophosphamide and the 4-hydroxycyclophosphamide metabolite in human plasma","volume":"1086","author":"Hall","year":"2018","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1124\/pharmrev.120.000121_bib137","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1038\/bjc.2013.798","article-title":"Pazopanib exposure decreases as a result of an ifosfamide-dependent drug-drug interaction: results of a phase I study","volume":"110","author":"Hamberg","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1124\/pharmrev.120.000121_bib138","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1038\/sj.bjc.6605696","article-title":"Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies","volume":"102","author":"Hamberg","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1124\/pharmrev.120.000121_bib139","first-page":"3791","article-title":"The Effects of N-acetylcysteine on ifosfamide efficacy in a mouse xenograft model","volume":"32","author":"Hanly","year":"2012","journal-title":"Anticancer Res"},{"key":"10.1124\/pharmrev.120.000121_bib140","first-page":"e132","article-title":"N-acetylcysteine rescue protocol for nephrotoxicity in children caused by ifosfamide","volume":"20","author":"Hanly","year":"2013","journal-title":"J Popul Ther Clin Pharmacol"},{"key":"10.1124\/pharmrev.120.000121_bib141","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1111\/bjd.15930","article-title":"British Association of Dermatologists\u2019 guidelines for the management of pemphigus vulgaris 2017","volume":"177","author":"Harman","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1124\/pharmrev.120.000121_bib142","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ejca.2019.10.016","article-title":"Randomised phase II trial of trofosfamide vs. doxorubicin in elderly patients with untreated metastatic soft-tissue sarcoma","volume":"124","author":"Hartmann","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1124\/pharmrev.120.000121_bib143","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2147\/DDDT.S279128","article-title":"Phenotyping study of cyclophosphamide 4-hydroxylation in Malay cancer patients","volume":"15","author":"Hasanah","year":"2021","journal-title":"Drug Des Devel Ther"},{"key":"10.1124\/pharmrev.120.000121_bib144","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/MOP.0000000000000041","article-title":"What is new in the biology and treatment of pediatric rhabdomyosarcoma?","volume":"26","author":"Hawkins","year":"2014","journal-title":"Curr Opin Pediatr"},{"key":"10.1124\/pharmrev.120.000121_bib145","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/bjc.1987.200","article-title":"Incidence of second primary tumours among childhood cancer survivors","volume":"56","author":"Hawkins","year":"1987","journal-title":"Br J Cancer"},{"key":"10.1124\/pharmrev.120.000121_bib146","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s00280-010-1530-7","article-title":"A phase I study of imatinib mesylate in combination with chlorambucil in previously treated chronic lymphocytic leukemia patients","volume":"68","author":"Hebb","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/pharmrev.120.000121_bib147","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1158\/1078-0432.CCR-20-4118","article-title":"A phase I dose-escalation study to evaluate the safety and tolerability of evofosfamide in combination with ipilimumab in advanced solid malignancies","volume":"27","author":"Hegde","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1124\/pharmrev.120.000121_bib148","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1111\/bcp.14031","article-title":"The importance of both CYP2C19 and CYP2B6 germline variations in cyclophosphamide pharmacokinetics and clinical outcomes","volume":"85","author":"Helsby","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/pharmrev.120.000121_bib149","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.suc.2012.12.002","article-title":"Adjuvant systemic therapies in breast cancer","volume":"93","author":"Hernandez-Aya","year":"2013","journal-title":"Surg Clin North Am"},{"key":"10.1124\/pharmrev.120.000121_bib150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083384","article-title":"Human CD4+CD25+ regulatory T cells are sensitive to low dose cyclophosphamide: implications for the immune response","volume":"8","author":"Heylmann","year":"2013","journal-title":"PLoS One"},{"key":"10.1124\/pharmrev.120.000121_bib151","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1093\/rheumatology\/ker105","article-title":"Causes and management of infertility in systemic lupus erythematosus","volume":"50","author":"Hickman","year":"2011","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl 15","key":"10.1124\/pharmrev.120.000121_bib152","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1200\/JCO.2018.36.15_suppl.2568","article-title":"Unexpected pharmacokinetics of evofosfamide observed in phase III MAESTRO study (Abstract)","volume":"36","author":"Higgins","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1124\/pharmrev.120.000121_bib153","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/1097-0215(19960301)65:5<711::AID-IJC2910650503>3.0.CO;2-H","article-title":"Preferential location of circulating activated cyclophosphamide within the erythrocyte","volume":"65","author":"Highley","year":"1996","journal-title":"Int J Cancer"},{"key":"10.1124\/pharmrev.120.000121_bib154","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1023\/A:1008261203803","article-title":"Activated oxazaphosphorines are transported predominantly by erythrocytes","volume":"8","author":"Highley","year":"1997","journal-title":"Ann Oncol"},{"key":"10.1124\/pharmrev.120.000121_bib155","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1093\/ndt\/gfq017","article-title":"Alkylating agents in membranous nephropathy: efficacy proven beyond doubt","volume":"25","author":"Hofstra","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1124\/pharmrev.120.000121_bib156","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1136\/ard.2008.102533","article-title":"The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide","volume":"69","author":"Houssiau","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1124\/pharmrev.120.000121_bib157","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s00280-019-03786-6","article-title":"Determination of melphalan in human plasma by UPLC-UV method","volume":"83","author":"Huang","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/pharmrev.120.000121_bib158","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s00262-018-2248-3","article-title":"Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma","volume":"68","author":"Huijts","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"10.1124\/pharmrev.120.000121_bib159","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.lfs.2018.12.018","article-title":"Molecular mechanism involved in cyclophosphamide-induced cardiotoxicity: Old drug with a new vision","volume":"218","author":"Iqubal","year":"2019","journal-title":"Life Sci"},{"key":"10.1124\/pharmrev.120.000121_bib160","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.122204","article-title":"Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma","volume":"3","author":"Jamieson","year":"2018","journal-title":"JCI Insight"},{"key":"10.1124\/pharmrev.120.000121_bib161","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.neuro.2016.06.013","article-title":"A clinically relevant dose of cyclophosphamide chemotherapy impairs memory performance on the delayed spatial alternation task that is sustained over time as mice age","volume":"56","author":"Janelsins","year":"2016","journal-title":"Neurotoxicology"},{"key":"10.1124\/pharmrev.120.000121_bib162","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1021\/mp500104j","article-title":"Structural modifications of mitochondria-targeted chlorambucil alter cell death mechanism but preserve MDR evasion","volume":"11","author":"Jean","year":"2014","journal-title":"Mol Pharm"},{"key":"10.1124\/pharmrev.120.000121_bib163","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.freeradbiomed.2017.05.006","article-title":"Cyclophosphamide and acrolein induced oxidative stress leading to deterioration of metaphase II mouse oocyte quality","volume":"110","author":"Jeelani","year":"2017","journal-title":"Free Radic Biol Med"},{"key":"10.1124\/pharmrev.120.000121_bib164","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1200\/JCO.2008.18.4028","article-title":"Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research trial 9735","volume":"27","author":"Jones","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1124\/pharmrev.120.000121_bib165","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1470-2045(14)70063-4","article-title":"Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial","volume":"15","author":"Judson","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1124\/pharmrev.120.000121_bib166","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0378-4347(93)80316-V","article-title":"Determination of chloroacetaldehyde, a metabolite of oxazaphosphorine cytostatic drugs, in plasma","volume":"614","author":"Kaijser","year":"1993","journal-title":"J Chromatogr A"},{"key":"10.1124\/pharmrev.120.000121_bib167","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jchromb.2006.03.022","article-title":"Rapid quantitation of cyclophosphamide metabolites in plasma by liquid chromatography-mass spectrometry","volume":"835","author":"Kalhorn","year":"2006","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1124\/pharmrev.120.000121_bib168","doi-asserted-by":"crossref","first-page":"211ra157","DOI":"10.1126\/scitranslmed.3006960","article-title":"Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide","volume":"5","author":"Kanakry","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1124\/pharmrev.120.000121_bib169","doi-asserted-by":"crossref","first-page":"439","DOI":"10.4103\/0378-6323.82396","article-title":"Pemphigus in India","volume":"77","author":"Kanwar","year":"2011","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1124\/pharmrev.120.000121_bib170","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1182\/blood-2015-05-647420","article-title":"Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenstr\u00f6m macroglobulinemia: final analysis of a phase 2 study","volume":"126","author":"Kastritis","year":"2015","journal-title":"Blood"},{"key":"10.1124\/pharmrev.120.000121_bib171","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.3389\/fimmu.2019.03138","article-title":"Cyclophosphamide-induced tolerance in allogeneic transplantation: from basic studies to clinical application","volume":"10","author":"Kato","year":"2020","journal-title":"Front Immunol"},{"key":"10.1124\/pharmrev.120.000121_bib172","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1038\/bjc.2013.553","article-title":"A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer","volume":"109","author":"Kelley","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1124\/pharmrev.120.000121_bib173","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1038\/bjc.2011.154","article-title":"Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer","volume":"104","author":"Khan","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1124\/pharmrev.120.000121_bib174","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00280-010-1274-4","article-title":"Penetration of ifosfamide and its active metabolite 4-OH-ifosfamide into cerebrospinal fluid of patients with CNS malignancies","volume":"67","author":"Kiewe","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/pharmrev.120.000121_bib175","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s00228-013-1507-7","article-title":"Population pharmacokinetics analysis of cyclophosphamide with genetic effects in patients undergoing hematopoietic stem cell transplantation","volume":"69","author":"Kim","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/pharmrev.120.000121_bib176","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s12185-013-1440-7","article-title":"Phase II study of ifosfamide, etoposide, and oxaliplatin (IFETOx) chemotherapy for relapsed or refractory non-Hodgkin\u2019s lymphoma","volume":"98","author":"Kim","year":"2013","journal-title":"Int J Hematol"},{"key":"10.1124\/pharmrev.120.000121_bib177","doi-asserted-by":"crossref","first-page":"1","DOI":"10.17077\/2154-4751.1457","article-title":"The effect of gonadotropin-releasing hormone analogues on the preservation of ovarian function against cyclophosphamide-induced damage in adult mice","volume":"9","author":"Kishk","year":"2020","journal-title":"Proc Obstet Gynecol"},{"key":"10.1124\/pharmrev.120.000121_bib178","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1136\/ard.2003.019125","article-title":"Urinary bladder cancer in Wegener\u2019s granulomatosis: risks and relation to cyclophosphamide","volume":"63","author":"Knight","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1124\/pharmrev.120.000121_bib179","doi-asserted-by":"crossref","first-page":"6549","DOI":"10.1200\/JCO.2005.19.638","article-title":"Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors","volume":"23","author":"Kondagunta","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1124\/pharmrev.120.000121_bib180","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/jso.23553","article-title":"Isolated limb infusion with melphalan and actinomycin D for melanoma: a systematic review","volume":"109","author":"Kroon","year":"2014","journal-title":"J Surg Oncol"},{"key":"10.1124\/pharmrev.120.000121_bib181","first-page":"497","article-title":"The blood and bone marrow in yellow cross gas (mustard gas) poisoning: changes produced in the bone marrow of fatal cases","volume":"40","author":"Krumbhaar","year":"1919","journal-title":"J Med Res"},{"key":"10.1124\/pharmrev.120.000121_bib182","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/FPC.0b013e3280ea77cd","article-title":"Genetic polymorphisms in the amino acid transporters LAT1 and LAT2 in relation to the pharmacokinetics and side effects of melphalan","volume":"17","author":"K\u00fchne","year":"2007","journal-title":"Pharmacogenet Genomics"},{"key":"10.1124\/pharmrev.120.000121_bib183","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/sj.clpt.6100336","article-title":"Population pharmacokinetics of melphalan and glutathione S-transferase polymorphisms in relation to side effects","volume":"83","author":"K\u00fchne","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pharmrev.120.000121_bib184","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/ajh.22053","article-title":"Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial","volume":"86","author":"Kumar","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1124\/pharmrev.120.000121_bib185","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s002280050102","article-title":"Methylene blue and the neurotoxic mechanisms of ifosfamide encephalopathy","volume":"50","author":"K\u00fcpfer","year":"1996","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/pharmrev.120.000121_bib186","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/BF00686020","article-title":"Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde, and 2- and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy","volume":"33","author":"Kurowski","year":"1993","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/pharmrev.120.000121_bib187","doi-asserted-by":"crossref","first-page":"72","DOI":"10.2174\/1874467211666181010161836","article-title":"Combination treatment of p53-null HL-60 cells with histone deacetylase inhibitors and chlorambucil augments apoptosis and increases BCL6 and p21 gene expression","volume":"12","author":"Kwa","year":"2019","journal-title":"Curr Mol Pharmacol"},{"key":"10.1124\/pharmrev.120.000121_bib188","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1046\/j.1365-2141.2000.01918.x","article-title":"Waldenstr\u00f6m\u2019s macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucil","volume":"108","author":"Kyle","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1124\/pharmrev.120.000121_bib189","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00204-010-0523-y","article-title":"Preservation of uroplakins by 2-mercaptoethanesulfonate in cyclophosphamide-induced rat cystitis","volume":"85","author":"Kyung","year":"2011","journal-title":"Arch Toxicol"},{"key":"10.1124\/pharmrev.120.000121_bib190","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ejca.2019.07.018","article-title":"Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study","volume":"119","author":"Le Cesne","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1124\/pharmrev.120.000121_bib191","first-page":"573","article-title":"Fatal cyclophosphamide cardiomyopathy: its clinical course and treatment","volume":"18","author":"Lee","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"10.1124\/pharmrev.120.000121_bib192","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41416-018-0349-6","article-title":"Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer","volume":"120","author":"Lee","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1124\/pharmrev.120.000121_bib193","first-page":"473536","article-title":"Cystitis: from urothelial cell biology to clinical applications","volume":"2014","author":"Lee","year":"2014","journal-title":"BioMed Res Int"},{"key":"10.1124\/pharmrev.120.000121_bib194","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.bcp.2010.06.002","article-title":"Comparative metabolism of cyclophosphamide and ifosfamide in the mouse using UPLC-ESI-QTOFMS-based metabolomics","volume":"80","author":"Li","year":"2010","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/pharmrev.120.000121_bib195","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/mt.2013.51","article-title":"Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients","volume":"21","author":"Liikanen","year":"2013","journal-title":"Mol Ther"},{"key":"10.1124\/pharmrev.120.000121_bib196","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2147\/DDDT.S137106","article-title":"Clinical potential of mechlorethamine gel for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma: a review on current efficacy and safety data","volume":"12","author":"Liner","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"10.1124\/pharmrev.120.000121_bib197","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1056\/NEJM198606193142502","article-title":"The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity","volume":"314","author":"Link","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.120.000121_bib198","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/j.1440-1681.2004.03065.x","article-title":"Application of liquid chromatography-mass spectrometry to monitoring plasma cyclophosphamide levels in phase I trial cancer patients","volume":"31","author":"Liu","year":"2004","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1124\/pharmrev.120.000121_bib199","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1158\/0008-5472.CAN-05-0646","article-title":"Immunostimulatory effects of low-dose cyclophosphamide are controlled by inducible nitric oxide synthase","volume":"65","author":"Loeffler","year":"2005","journal-title":"Cancer Res"},{"key":"10.1124\/pharmrev.120.000121_bib200","first-page":"121","article-title":"Safety, feasibility, and clinical benefit of localized chemotherapy using microencapsulated cells for inoperable pancreatic carcinoma in a phase I\/II trial","volume":"1","author":"L\u00f6hr","year":"2003","journal-title":"Cancer Ther"},{"key":"10.1124\/pharmrev.120.000121_bib201","doi-asserted-by":"crossref","first-page":"3808","DOI":"10.1200\/JCO.2009.27.5016","article-title":"Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children\u2019s Oncology Group study","volume":"28","author":"London","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1124\/pharmrev.120.000121_bib202","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.4049\/jimmunol.1401894","article-title":"Alkylating agent melphalan augments the efficacy of adoptive immunotherapy using tumor-specific CD4+ T cells","volume":"194","author":"Lu","year":"2015","journal-title":"J Immunol"},{"key":"10.1124\/pharmrev.120.000121_bib203","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1182\/blood-2004-06-2410","article-title":"Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide","volume":"105","author":"Lutsiak","year":"2005","journal-title":"Blood"},{"key":"10.1124\/pharmrev.120.000121_bib204","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0021445","article-title":"The effects of cyclophosphamide on hippocampal cell proliferation and spatial working memory in rat","volume":"6","author":"Lyons","year":"2011","journal-title":"PLoS One"},{"key":"10.1124\/pharmrev.120.000121_bib205","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s10753-011-9319-3","article-title":"Interleukin-4 modulates the inflammatory response in ifosfamide-induced hemorrhagic cystitis","volume":"35","author":"Macedo","year":"2012","journal-title":"Inflammation"},{"key":"10.1124\/pharmrev.120.000121_bib206","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1002\/pbc.24601","article-title":"Pilot study of cisplatin, etoposide, bleomycin, and escalating dose cyclophosphamide therapy for children with high risk germ cell tumors: a report of the children\u2019s oncology group (COG)","volume":"60","author":"Malogolowkin","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"10.1124\/pharmrev.120.000121_bib207","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.120.000121_bib208","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/S1470-2045(16)30214-5","article-title":"Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial","volume":"17","author":"Marina","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1124\/pharmrev.120.000121_bib209","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/hon.2154","article-title":"Chlorambucil-rituximab as first-line therapy in patients affected by follicular non-Hodgkin\u2019s lymphoma: a retrospective single-centre study","volume":"33","author":"Martinelli","year":"2015","journal-title":"Hematol Oncol"},{"key":"10.1124\/pharmrev.120.000121_bib210","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s10637-013-9989-9","article-title":"Phase I trial of sorafenib in combination with ifosfamide in patients with advanced sarcoma: a Spanish group for research on sarcomas (GEIS) study","volume":"32","author":"Mart\u00edn-Liberal","year":"2014","journal-title":"Invest New Drugs"},{"key":"10.1124\/pharmrev.120.000121_bib212","doi-asserted-by":"crossref","first-page":"102058","DOI":"10.1016\/j.ctrv.2020.102058","article-title":"Isolated limb perfusion for soft tissue sarcoma: current practices and future directions. A survey of experts and a review of literature","volume":"88","author":"Martin-Tellez","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"10.1124\/pharmrev.120.000121_bib213","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1007\/s00262-001-0237-3","article-title":"Th2\/Th1 switch induced by a single low dose of cyclophosphamide in a rat metastatic lymphoma model","volume":"50","author":"Matar","year":"2002","journal-title":"Cancer Immunol Immunother"},{"key":"10.1124\/pharmrev.120.000121_bib214","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/S0959-8049(00)00044-7","article-title":"Mechanism of antimetastatic immunopotentiation by low-dose cyclophosphamide","volume":"36","author":"Matar","year":"2000","journal-title":"Eur J Cancer"},{"key":"10.1124\/pharmrev.120.000121_bib215","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.urology.2016.07.030","article-title":"Review of advances in uroprotective agents for cyclophosphamide- and ifosfamide-induced hemorrhagic cystitis","volume":"100","author":"Matz","year":"2017","journal-title":"Urology"},{"key":"10.1124\/pharmrev.120.000121_bib216","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10549-012-2256-5","article-title":"Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics","volume":"136","author":"Mayer","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1124\/pharmrev.120.000121_bib217","first-page":"2783","article-title":"Mafosfamide as a new anticancer agent: preclinical investigations and clinical trials","volume":"32","author":"Mazur","year":"2012","journal-title":"Anticancer Res"},{"key":"10.1124\/pharmrev.120.000121_bib218","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1002\/cber.188601902358","article-title":"Ueber thiodiglykolverbindungen","volume":"19","author":"Meyer","year":"1886","journal-title":"Ber Dtsch Chem Ges"},{"key":"10.1124\/pharmrev.120.000121_bib219","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3389\/fonc.2017.00114","article-title":"Current immunotherapeutic strategies to enhance oncolytic virotherapy","volume":"7","author":"Meyers","year":"2017","journal-title":"Front Oncol"},{"issue":"Suppl 15","key":"10.1124\/pharmrev.120.000121_bib220","doi-asserted-by":"crossref","first-page":"11502","DOI":"10.1200\/JCO.2020.38.15_suppl.11502","article-title":"Results of the second interim assessment of rEECur, an international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES) (Abstract)","volume":"38","author":"McCabe","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1124\/pharmrev.120.000121_bib221","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/clpt.2009.27","article-title":"Personalized dosing of cyclophosphamide in the total body irradiation-cyclophosphamide conditioning regimen: a phase II trial in patients with hematologic malignancy","volume":"85","author":"McCune","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pharmrev.120.000121_bib222","doi-asserted-by":"crossref","first-page":"698","DOI":"10.3324\/haematol.2017.170480","article-title":"Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study","volume":"103","author":"Michallet","year":"2018","journal-title":"Haematologica"},{"key":"10.1124\/pharmrev.120.000121_bib223","doi-asserted-by":"crossref","first-page":"9170","DOI":"10.1021\/jm4012438","article-title":"A selective mitochondrial-targeted chlorambucil with remarkable cytotoxicity in breast and pancreatic cancers","volume":"56","author":"Millard","year":"2013","journal-title":"J Med Chem"},{"key":"10.1124\/pharmrev.120.000121_bib224","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/jhrc.1240170908","article-title":"Determination of iphosphamide and seven metabolites in blood plasma, as stable trifluoroacetyl derivatives, by electron capture chemical ionization GC-MS","volume":"17","author":"Momerency","year":"1994","journal-title":"J High Resolut Chromatogr"},{"key":"10.1124\/pharmrev.120.000121_bib225","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/bms.1200230306","article-title":"The determination of cyclophosphamide and its metabolites in blood plasma as stable trifluoroacetyl derivatives by electron capture chemical ionization gas chromatography\/mass spectrometry","volume":"23","author":"Momerency","year":"1994","journal-title":"Biol Mass Spectrom"},{"key":"10.1124\/pharmrev.120.000121_bib226","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Moreno","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1124\/pharmrev.120.000121_bib227","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1634\/theoncologist.2009-0325","article-title":"Isolated limb perfusion for malignant melanoma: systematic review on effectiveness and safety","volume":"15","author":"Moreno-Ramirez","year":"2010","journal-title":"Oncologist"},{"key":"10.1124\/pharmrev.120.000121_bib228","doi-asserted-by":"crossref","first-page":"6030","DOI":"10.1158\/1078-0432.CCR-12-3211","article-title":"Long-term follow-up of MRC Myeloma IX trial: Survival outcomes with bisphosphonate and thalidomide treatment","volume":"19","author":"Morgan","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1124\/pharmrev.120.000121_bib229","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1200\/JCO.2012.45.3308","article-title":"Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma","volume":"31","author":"Moskowitz","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1124\/pharmrev.120.000121_bib230","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood.V97.3.616","article-title":"A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model","volume":"97","author":"Moskowitz","year":"2001","journal-title":"Blood"},{"key":"10.1124\/pharmrev.120.000121_bib231","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/CND.0b013e31828ee913","article-title":"Efficacy and limitations of pulse cyclophosphamide therapy in polymyositis and dermatomyositis","volume":"14","author":"Nagappa","year":"2013","journal-title":"J Clin Neuromuscul Dis"},{"key":"10.1124\/pharmrev.120.000121_bib343","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1038\/s41409-019-0631-0","article-title":"Impact of frailty, melphalan pharmacokinetics, and pharmacogenetics on outcomes post autologous hematopoietic cell transplantation for multiple myeloma","volume":"54","author":"Nampoothiri","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1124\/pharmrev.120.000121_bib232","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.canlet.2018.06.002","article-title":"Does metronomic chemotherapy induce tumor angiogenic dormancy? A review of available preclinical and clinical data","volume":"432","author":"Natale","year":"2018","journal-title":"Cancer Lett"},{"key":"10.1124\/pharmrev.120.000121_bib233","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/j.1365-2125.2010.03638.x","article-title":"Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy","volume":"69","author":"Nath","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/pharmrev.120.000121_bib234","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/bcp.12906","article-title":"High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation","volume":"82","author":"Nath","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/pharmrev.120.000121_bib235","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1158\/1078-0432.CCR-12-1897","article-title":"Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory\/recurrent solid tumors","volume":"19","author":"Navid","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1124\/pharmrev.120.000121_bib236","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1365-2125.1983.tb01494.x","article-title":"Studies on the pharmacokinetics of chlorambucil and prednimustine in man","volume":"15","author":"Newell","year":"1983","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/pharmrev.120.000121_bib237","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/jso.23558","article-title":"Isolated limb perfusion with melphalan for melanoma","volume":"109","author":"Nieweg","year":"2014","journal-title":"J Surg Oncol"},{"key":"10.1124\/pharmrev.120.000121_bib238","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0131394","article-title":"Mechanisms of fatal cardiotoxicity following high-dose cyclophosphamide therapy and a method for its prevention","volume":"10","author":"Nishikawa","year":"2015","journal-title":"PLoS One"},{"key":"10.1124\/pharmrev.120.000121_bib239","doi-asserted-by":"crossref","first-page":"7824","DOI":"10.1158\/0008-5472.CAN-06-1043","article-title":"Ifosfamide-induced nephrotoxicity: mechanism and prevention","volume":"66","author":"Nissim","year":"2006","journal-title":"Cancer Res"},{"key":"10.1124\/pharmrev.120.000121_bib240","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.3389\/fimmu.2019.02668","article-title":"Mechanisms of graft-versus-host disease prevention by post-transplantation cyclophosphamide: an evolving understanding","volume":"10","author":"Nunes","year":"2019","journal-title":"Front Immunol"},{"key":"10.1124\/pharmrev.120.000121_bib241","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/bjh.16625","article-title":"A five-year follow-up of untreated patients with chronic lymphocytic leukaemia treated with ofatumumab and chlorambucil: final analysis of the Complement 1 phase 3 trial","volume":"190","author":"Offner","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1124\/pharmrev.120.000121_bib242","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jpba.2007.07.026","article-title":"Enantioselective liquid chromatography-mass spectrometry assay for the determination of ifosfamide and identification of the N-dechloroethylated metabolites of ifosfamide in human plasma","volume":"45","author":"Oliveira","year":"2007","journal-title":"J Pharm Biomed Anal"},{"key":"10.1124\/pharmrev.120.000121_bib243","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1080\/13543784.2020.1808884","article-title":"Melflufen for relapsed and refractory multiple myeloma","volume":"29","author":"Oriol","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1124\/pharmrev.120.000121_bib244","first-page":"167","article-title":"Hemorrhagic cystitis after bone marrow transplantation","volume":"67","author":"Padilla-Fernandez","year":"2014","journal-title":"Arch Esp Urol"},{"key":"10.1124\/pharmrev.120.000121_bib245","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1080\/1744666X.2019.1656527","article-title":"Treatment of systemic necrotizing vasculitides: recent advances and important clinical considerations","volume":"15","author":"Pagnoux","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1124\/pharmrev.120.000121_bib246","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3324\/haematol.2013.095463","article-title":"Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach","volume":"99","author":"Palladini","year":"2014","journal-title":"Haematologica"},{"key":"10.1124\/pharmrev.120.000121_bib247","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous transplantation and maintenance therapy in multiple myeloma","volume":"371","author":"Palumbo","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.120.000121_bib248","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1158\/1078-0432.CCR-19-2609","article-title":"First-in-human study of cemiplimab alone or in combination with radiotherapy and\/or low-dose cyclophosphamide in patients with advanced malignancies","volume":"26","author":"Papadopoulos","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1124\/pharmrev.120.000121_bib249","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s10637-009-9320-y","article-title":"Salvage therapy with gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOX) for B-cell non-Hodgkin\u2019s lymphoma: a consortium for improving survival of lymphoma (CISL) trial","volume":"29","author":"Park","year":"2011","journal-title":"Invest New Drugs"},{"issue":"Suppl 15","key":"10.1124\/pharmrev.120.000121_bib250","article-title":"Phase II study of low-dose cyclophosphamide and ipilimumab in metastatic melanoma (Abstract)","volume":"32","author":"Pavlick","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1124\/pharmrev.120.000121_bib251","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1111\/bju.12291","article-title":"Chemical- and radiation-induced haemorrhagic cystitis: current treatments and challenges","volume":"112","author":"Payne","year":"2013","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.120.000121_bib252","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/cncr.23592","article-title":"A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma","volume":"113","author":"Pervaiz","year":"2008","journal-title":"Cancer"},{"key":"10.1124\/pharmrev.120.000121_bib253","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S0140-6736(11)61625-5","article-title":"Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials","volume":"379","author":"Peto","year":"2012","journal-title":"Lancet"},{"key":"10.1124\/pharmrev.120.000121_bib254","doi-asserted-by":"crossref","first-page":"6117","DOI":"10.1200\/JCO.2005.06.075","article-title":"Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer","volume":"23","author":"Petros","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1124\/pharmrev.120.000121_bib255","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1124\/pharmrev.120.000121_bib256","doi-asserted-by":"crossref","first-page":"67","DOI":"10.21873\/anticanres.13080","article-title":"A single nucleotide polymorphism in SLC7A5 was associated with clinical response in multiple myeloma patients","volume":"39","author":"Poi","year":"2019","journal-title":"Anticancer Res"},{"key":"10.1124\/pharmrev.120.000121_bib257","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0165-1110(94)90015-9","article-title":"DNA damage and mutagenesis induced by nitrogen mustards","volume":"318","author":"Povirk","year":"1994","journal-title":"Mutat Res"},{"key":"10.1124\/pharmrev.120.000121_bib258","first-page":"CD002290","article-title":"Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children","volume":"10","author":"Pravitsitthikul","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1124\/pharmrev.120.000121_bib259","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/s00280-003-0757-y","article-title":"Investigations on the pharmacokinetics of trofosfamide and its metabolites-first report of 4-hydroxy-trofosfamide kinetics in humans","volume":"53","author":"Preiss","year":"2004","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/pharmrev.120.000121_bib260","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1038\/bjc.2013.64","article-title":"In vivo RAF signal transduction as a potential biomarker for sorafenib efficacy in patients with neuroendocrine tumours","volume":"108","author":"Quintela-Fandino","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1124\/pharmrev.120.000121_bib261","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00262-009-0734-3","article-title":"Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell elimination","volume":"59","author":"Radojcic","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"10.1124\/pharmrev.120.000121_bib262","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.thorsurg.2010.08.003","article-title":"Chemotherapy for thymic tumors: induction, consolidation, palliation","volume":"21","author":"Rajan","year":"2011","journal-title":"Thorac Surg Clin"},{"key":"10.1124\/pharmrev.120.000121_bib263","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nrclinonc.2011.63","article-title":"Treatment of multiple myeloma","volume":"8","author":"Rajkumar","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1124\/pharmrev.120.000121_bib264","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/leu.2009.26","article-title":"Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial","volume":"23","author":"Reeder","year":"2009","journal-title":"Leukemia"},{"key":"10.1124\/pharmrev.120.000121_bib265","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1177\/1352458510383609","article-title":"Autologous hematopoietic cell transplantation for multiple sclerosis: a systematic review","volume":"17","author":"Reston","year":"2011","journal-title":"Mult Scler"},{"key":"10.1124\/pharmrev.120.000121_bib266","doi-asserted-by":"crossref","first-page":"e395","DOI":"10.1016\/S2352-3026(20)30044-2","article-title":"Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study","volume":"7","author":"Richardson","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1124\/pharmrev.120.000121_bib267","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/ajh.22054","article-title":"Effectiveness and safety of high-dose cyclophosphamide as salvage therapy for high-risk multiple myeloma and plasma cell leukemia refractory to new biological agents","volume":"86","author":"Rivell","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1124\/pharmrev.120.000121_bib268","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/oxfordjournals.annonc.a059252","article-title":"A phase II trial of mesna\/ifosfamide, mitoxantrone and etoposide for refractory lymphomas","volume":"6","author":"Rodriguez","year":"1995","journal-title":"Ann Oncol"},{"key":"10.1124\/pharmrev.120.000121_bib269","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1200\/JCO.2016.67.6684","article-title":"PICASSO III: a phase III, placebo-controlled study of doxorubicin with or without palifosfamide in patients with metastatic soft tissue sarcoma","volume":"34","author":"Ryan","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1124\/pharmrev.120.000121_bib270","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.1995.13.7.1786","article-title":"High-dose intravenous melphalan: a review","volume":"13","author":"Samuels","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1124\/pharmrev.120.000121_bib271","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3324\/haematol.10661","article-title":"Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin\u2019s lymphoma","volume":"92","author":"Santoro","year":"2007","journal-title":"Haematologica"},{"key":"10.1124\/pharmrev.120.000121_bib272","doi-asserted-by":"crossref","first-page":"452902","DOI":"10.1155\/2012\/452902","article-title":"Inhibition of gene expression of organic cation\/carnitine transporter and antioxidant enzymes in oxazaphosphorines-induced acute cardiomyopathic rat models","volume":"2012","author":"Sayed-Ahmed","year":"2012","journal-title":"Oxid Med Cell Longev"},{"key":"10.1124\/pharmrev.120.000121_bib273","doi-asserted-by":"crossref","first-page":"696704","DOI":"10.1155\/2012\/696704","article-title":"Downregulation of oxidative and nitrosative apoptotic signaling by L-carnitine in Ifosfamide-induced Fanconi syndrome rat model","volume":"2012","author":"Sayed-Ahmed","year":"2012","journal-title":"Oxid Med Cell Longev"},{"key":"10.1124\/pharmrev.120.000121_bib274","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1200\/JCO.2001.19.15.3463","article-title":"Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study","volume":"19","author":"Saylors","year":"2001","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"10.1124\/pharmrev.120.000121_bib275","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/S2152-2650(21)02124-8","volume":"21","author":"Schjesvold","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1124\/pharmrev.120.000121_bib276","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2217\/fon-2020-0024","article-title":"OCEAN: a randomized Phase III study of melflufen + dexamethasone to treat relapsed refractory multiple myeloma","volume":"16","author":"Schjesvold","year":"2020","journal-title":"Future Oncol"},{"key":"10.1124\/pharmrev.120.000121_bib277","doi-asserted-by":"crossref","first-page":"121711","DOI":"10.1016\/j.jchromb.2019.121711","article-title":"Measurement of the DNA alkylating agents busulfan and melphalan in human plasma by mass spectrometry","volume":"1125","author":"Schofield","year":"2019","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1124\/pharmrev.120.000121_bib278","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1124\/mol.60.6.1268","article-title":"Cyclophosphamide induces caspase 9-dependent apoptosis in 9L tumor cells","volume":"60","author":"Schwartz","year":"2001","journal-title":"Mol Pharmacol"},{"key":"10.1124\/pharmrev.120.000121_bib279","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.2579","article-title":"Effect of modified vaccinia Ankara-5T4 and low-dose cyclophosphamide on antitumor immunity in metastatic colorectal cancer: a randomized clinical trial","volume":"3","author":"Scurr","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1124\/pharmrev.120.000121_bib280","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3322\/caac.21438","article-title":"Hodgkin lymphoma: a review and update on recent progress","volume":"68","author":"Shanbhag","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1124\/pharmrev.120.000121_bib281","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.ejca.2011.10.018","article-title":"Treatment outcome after low intensity chemotherapy [CVP] in children and adolescents with early stage nodular lymphocyte predominant Hodgkin\u2019s lymphoma - an Anglo-French collaborative report","volume":"48","author":"Shankar","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1124\/pharmrev.120.000121_bib282","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1038\/bmt.2014.186","article-title":"Not too little, not too much-just right! (Better ways to give high dose melphalan)","volume":"49","author":"Shaw","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1124\/pharmrev.120.000121_bib283","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00280-009-1028-3","article-title":"Phase I clinical and pharmacokinetic study of the glucose-conjugated cytotoxic agent D-19575 (glufosfamide) in patients with solid tumors","volume":"65","author":"Shimizu","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/pharmrev.120.000121_bib284","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/cas.13193","article-title":"A randomized phase II trial of personalized peptide vaccine with low dose cyclophosphamide in biliary tract cancer","volume":"108","author":"Shirahama","year":"2017","journal-title":"Cancer Sci"},{"key":"10.1124\/pharmrev.120.000121_bib285","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1515\/CCLM.2011.710","volume":"49","author":"Shu","year":"2011","journal-title":"Clin Chem Lab Med"},{"key":"10.1124\/pharmrev.120.000121_bib286","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1034\/j.1600-0773.2000.pto870506.x","article-title":"Pharmacokinetics of chlorambucil in patients with chronic lymphocytic leukaemia: comparison of different days, cycles and doses","volume":"87","author":"Silvennoinen","year":"2000","journal-title":"Pharmacol Toxicol"},{"key":"10.1124\/pharmrev.120.000121_bib287","doi-asserted-by":"crossref","first-page":"5483791","DOI":"10.1155\/2019\/5483791","article-title":"Metronomic chemotherapy: a systematic review of the literature and clinical experience","volume":"2019","author":"Simsek","year":"2019","journal-title":"J Oncol"},{"key":"10.1124\/pharmrev.120.000121_bib288","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00281-011-0245-0","article-title":"Immunomodulatory effects of cyclophosphamide and implementations for vaccine design","volume":"33","author":"Sistigu","year":"2011","journal-title":"Semin Immunopathol"},{"key":"10.1124\/pharmrev.120.000121_bib289","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/0163-7258(88)90004-6","article-title":"Metabolism of oxazaphosphorines","volume":"37","author":"Sladek","year":"1988","journal-title":"Pharmacol Ther"},{"key":"10.1124\/pharmrev.120.000121_bib290","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1124\/jpet.103.057729","article-title":"Role of multidrug resistance protein 2 (MRP2, ABCC2) in alkylating agent detoxification: MRP2 potentiates glutathione S-transferase A1-1-mediated resistance to chlorambucil cytotoxicity","volume":"308","author":"Smitherman","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.120.000121_bib291","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/bmt.2010.147","article-title":"Independence of exogenous insulin following immunoablation and stem cell reconstitution in newly diagnosed diabetes type I","volume":"46","author":"Snarski","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1124\/pharmrev.120.000121_bib292","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0055493","article-title":"An inverse switch in DNA base excision and strand break repair contributes to melphalan resistance in multiple myeloma cells","volume":"8","author":"Sousa","year":"2013","journal-title":"PLoS One"},{"key":"10.1124\/pharmrev.120.000121_bib293","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.jchromb.2011.05.003","article-title":"Liquid chromatography-tandem mass spectrometric assay for the PARP-1 inhibitor olaparib in combination with the nitrogen mustard melphalan in human plasma","volume":"879","author":"Sparidans","year":"2011","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1124\/pharmrev.120.000121_bib294","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/humupd\/dmz027","article-title":"Ovarian damage from chemotherapy and current approaches to its protection","volume":"25","author":"Spears","year":"2019","journal-title":"Hum Reprod Update"},{"key":"10.1124\/pharmrev.120.000121_bib295","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1007\/s11626-999-0080-y","article-title":"Toxicity of ifosfamide and its metabolite chloroacetaldehyde in cultured renal tubule cells","volume":"35","author":"Springate","year":"1999","journal-title":"In Vitro Cell Dev Biol Anim"},{"key":"10.1124\/pharmrev.120.000121_bib296","first-page":"831","article-title":"Low-dose oral metronomic chemotherapy prevents mobilization of endothelial progenitor cells into the blood of cancer patients","volume":"22","author":"Stoelting","year":"2008","journal-title":"In Vivo"},{"key":"10.1124\/pharmrev.120.000121_bib297","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/bjc.1983.2","article-title":"Isophosphoramide mustard, a metabolite of ifosfamide with activity against murine tumours comparable to cyclophosphamide","volume":"47","author":"Struck","year":"1983","journal-title":"Br J Cancer"},{"key":"10.1124\/pharmrev.120.000121_bib298","first-page":"5621","article-title":"Association between survival after treatment for breast cancer and glutathione S-transferase P1 Ile105Val polymorphism","volume":"60","author":"Sweeney","year":"2000","journal-title":"Cancer Res"},{"key":"10.1124\/pharmrev.120.000121_bib299","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1002\/art.20338","article-title":"Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis","volume":"50","author":"Takada","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1124\/pharmrev.120.000121_bib300","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S1470-2045(17)30381-9","article-title":"Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406\/SARC021): an international, multicentre, open-label, randomised phase 3 trial","volume":"18","author":"Tap","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1124\/pharmrev.120.000121_bib301","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0143421","article-title":"A new method to quantify ifosfamide blood levels using dried blood spots and UPLC-MS\/MS in paediatric patients with embryonic solid tumours","volume":"10","author":"Torres","year":"2015","journal-title":"PLoS One"},{"key":"10.1124\/pharmrev.120.000121_bib302","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1001\/jamaoncol.2017.1617","article-title":"Use of PD-1 targeting, macrophage infiltration, and IDO pathway activation in sarcomas: a phase 2 clinical trial","volume":"4","author":"Toulmonde","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1124\/pharmrev.120.000121_bib303","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.4065\/80.12.1578","article-title":"Weekly cyclophosphamide and alternate-day prednisone: an effective, convenient, and well-tolerated oral treatment for relapsed multiple myeloma after autologous stem cell transplantation","volume":"80","author":"Trieu","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"10.1124\/pharmrev.120.000121_bib304","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1089\/jir.2014.0106","article-title":"Interferon alpha and metronomic cyclophosphamide for metastatic kidney cancer: a phase 2 study","volume":"35","author":"Tupikowski","year":"2015","journal-title":"J Interferon Cytokine Res"},{"key":"10.1124\/pharmrev.120.000121_bib305","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1001\/archsurg.2011.139","article-title":"Limb preservation with isolated limb infusion for locally advanced nonmelanoma cutaneous and soft-tissue malignant neoplasms","volume":"146","author":"Turaga","year":"2011","journal-title":"Arch Surg"},{"key":"10.1124\/pharmrev.120.000121_bib306","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s00277-013-1879-x","article-title":"Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma","volume":"93","author":"Vacirca","year":"2014","journal-title":"Ann Hematol"},{"issue":"Suppl 15","key":"10.1124\/pharmrev.120.000121_bib307","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1200\/JCO.2016.34.15_suppl.4007","article-title":"MAESTRO: a randomized, double-blind phase III study of evofosfamide (Evo) in combination with gemcitabine (Gem) in previously untreated patients (pts) with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC) (Abstract)","volume":"34","author":"Van Cutsem","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1124\/pharmrev.120.000121_bib308","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.2147\/OTT.S170585","article-title":"Management of recurrent Ewing sarcoma: challenges and approaches","volume":"12","author":"Van Mater","year":"2019","journal-title":"OncoTargets Ther"},{"key":"10.1124\/pharmrev.120.000121_bib309","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3389\/fimmu.2019.00008","article-title":"Vaccine strategies to improve anti-cancer cellular immune responses","volume":"10","author":"Vermaelen","year":"2019","journal-title":"Front Immunol"},{"key":"10.1124\/pharmrev.120.000121_bib310","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s00467-004-1759-7","article-title":"The response to cyclophosphamide in steroid-sensitive nephrotic syndrome is influenced by polymorphic expression of glutathion-S-transferases-M1 and -P1","volume":"20","author":"Vester","year":"2005","journal-title":"Pediatr Nephrol"},{"key":"10.1124\/pharmrev.120.000121_bib311","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1158\/0008-5472.CAN-14-0987","article-title":"Harnessing the intestinal microbiome for optimal therapeutic immunomodulation","volume":"74","author":"Viaud","year":"2014","journal-title":"Cancer Res"},{"key":"10.1124\/pharmrev.120.000121_bib312","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1158\/0008-5472.CAN-10-1259","article-title":"Cyclophosphamide induces differentiation of Th17 cells in cancer patients","volume":"71","author":"Viaud","year":"2011","journal-title":"Cancer Res"},{"key":"10.1124\/pharmrev.120.000121_bib313","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1126\/science.1240537","article-title":"The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide","volume":"342","author":"Viaud","year":"2013","journal-title":"Science"},{"key":"10.1124\/pharmrev.120.000121_bib314","first-page":"193","article-title":"Thiodiglycolic acid is excreted by humans receiving ifosfamide and inhibits mitochondrial function in rats","volume":"26","author":"Visarius","year":"1998","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pharmrev.120.000121_bib315","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S0022-3565(24)38206-0","article-title":"Inhibition and stimulation of long-chain fatty acid oxidation by chloroacetaldehyde and methylene blue in rats","volume":"289","author":"Visarius","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.120.000121_bib316","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1100340","article-title":"ABVD versus BEACOPP for Hodgkin\u2019s lymphoma when high-dose salvage is planned","volume":"365","author":"Viviani","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.120.000121_bib317","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/00001813-199706000-00002","article-title":"Trofosfamide: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the oral treatment of cancer","volume":"8","author":"Wagner","year":"1997","journal-title":"Anticancer Drugs"},{"key":"10.1124\/pharmrev.120.000121_bib318","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000533","article-title":"Haematopoietic stem cell transplantation in systemic sclerosis","volume":"4","author":"Walker","year":"2018","journal-title":"RMD Open"},{"key":"10.1124\/pharmrev.120.000121_bib319","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/nm.2883","article-title":"Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival","volume":"18","author":"Walter","year":"2012","journal-title":"Nat Med"},{"key":"10.1124\/pharmrev.120.000121_bib320","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.clim.2015.07.010","article-title":"The GSTA1 polymorphism and cyclophosphamide therapy outcomes in lupus nephritis patients","volume":"160","author":"Wang","year":"2015","journal-title":"Clin Immunol"},{"key":"10.1124\/pharmrev.120.000121_bib321","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1021\/bc5004108","article-title":"Scopine as a novel brain-targeting moiety enhances the brain uptake of chlorambucil","volume":"25","author":"Wang","year":"2014","journal-title":"Bioconjug Chem"},{"key":"10.1124\/pharmrev.120.000121_bib322","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1136\/bmj.291.6507.1457","article-title":"Long term effects of cyclophosphamide on testicular function","volume":"291","author":"Watson","year":"1985","journal-title":"Br Med J (Clin Res Ed)"},{"key":"10.1124\/pharmrev.120.000121_bib323","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41408-019-0206-8","article-title":"Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial","volume":"9","author":"Weisel","year":"2019","journal-title":"Blood Cancer J"},{"key":"10.1124\/pharmrev.120.000121_bib324","doi-asserted-by":"crossref","first-page":"66641","DOI":"10.18632\/oncotarget.18420","article-title":"Melflufen - a peptidase-potentiated alkylating agent in clinical trials","volume":"8","author":"Wickstr\u00f6m","year":"2017","journal-title":"Oncotarget"},{"key":"10.1124\/pharmrev.120.000121_bib325","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/(SICI)1520-636X(1999)11:4<301::AID-CHIR7>3.0.CO;2-R","article-title":"Pharmacokinetics of (R)- and (S)-cyclophosphamide and their dechloroethylated metabolites in cancer patients","volume":"11","author":"Williams","year":"1999","journal-title":"Chirality"},{"key":"10.1124\/pharmrev.120.000121_bib326","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00432-018-2772-8","article-title":"Trofosfamide in the treatment of elderly or frail patients with diffuse large B-cell lymphoma","volume":"145","author":"Witte","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1124\/pharmrev.120.000121_bib327","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S1470-2045(12)70346-7","article-title":"Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial","volume":"13","author":"Woll","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1124\/pharmrev.120.000121_bib328","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1200\/JCO.2011.41.5703","article-title":"Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children\u2019s Oncology Group","volume":"30","author":"Womer","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1124\/pharmrev.120.000121_bib329","doi-asserted-by":"crossref","first-page":"64089","DOI":"10.18632\/oncotarget.11596","article-title":"Phase Ib\/II randomized, open-label study of doxorubicin and cyclophosphamide with or without low-dose, short-course sunitinib in the pre-operative treatment of breast cancer","volume":"7","author":"Wong","year":"2016","journal-title":"Oncotarget"},{"key":"10.1124\/pharmrev.120.000121_bib330","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1200\/JCO.2011.41.5646","article-title":"Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies","volume":"31","author":"Woyach","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1124\/pharmrev.120.000121_bib331","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.3109\/10428194.2012.743657","article-title":"Risk of second malignant neoplasms after cyclophosphamide-based chemotherapy with or without radiotherapy for non-Hodgkin lymphoma","volume":"54","author":"Xu","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1124\/pharmrev.120.000121_bib332","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1631\/jzus.B1800640","article-title":"Systematic review and meta-analysis of the efficacy and safety of immunosuppressive pulse therapy in the treatment of paraquat poisoning","volume":"20","author":"Xu","year":"2019","journal-title":"J Zhejiang Univ Sci B"},{"key":"10.1124\/pharmrev.120.000121_bib333","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.3389\/fimmu.2018.01739","article-title":"Combining immune checkpoint inhibitors with conventional cancer therapy","volume":"9","author":"Yan","year":"2018","journal-title":"Front Immunol"},{"key":"10.1124\/pharmrev.120.000121_bib334","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1590\/S0004-27492010000100007","article-title":"Chlorambucil and cyclosporine A in Brazilian patients with Beh\u00e7et\u2019s disease uveitis: a retrospective study","volume":"73","author":"Zaghetto","year":"2010","journal-title":"Arq Bras Oftalmol"},{"key":"10.1124\/pharmrev.120.000121_bib335","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1006\/taap.1994.1241","article-title":"Ifosfamide metabolite chloroacetaldehyde causes Fanconi syndrome in the perfused rat kidney","volume":"129","author":"Zamlauski-Tucker","year":"1994","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1124\/pharmrev.120.000121_bib336","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1208\/s12248-010-9189-x","article-title":"Interaction of oxazaphosphorines with multidrug resistance-associated protein 4 (MRP4)","volume":"12","author":"Zhang","year":"2010","journal-title":"AAPS J"},{"key":"10.1124\/pharmrev.120.000121_bib337","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1080\/03602530500364023","article-title":"Metabolism and transport of oxazaphosphorines and the clinical implications","volume":"37","author":"Zhang","year":"2005","journal-title":"Drug Metab Rev"},{"key":"10.1124\/pharmrev.120.000121_bib338","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2174\/157488506775268515","article-title":"Clinical pharmacology of cyclophosphamide and ifosfamide","volume":"1","author":"Zhang","year":"2006","journal-title":"Curr Drug Ther"},{"key":"10.1124\/pharmrev.120.000121_bib339","doi-asserted-by":"crossref","first-page":"4850","DOI":"10.1158\/0008-5472.CAN-10-0283","article-title":"Selective depletion of CD4+CD25+Foxp3+ regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels","volume":"70","author":"Zhao","year":"2010","journal-title":"Cancer Res"},{"key":"10.1124\/pharmrev.120.000121_bib340","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1365-2125.2006.02690.x","article-title":"Relationship of glutathione S-transferase genotypes with side-effects of pulsed cyclophosphamide therapy in patients with systemic lupus erythematosus","volume":"62","author":"Zhong","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/pharmrev.120.000121_bib341","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/01.mph.0000187429.52616.8a","article-title":"Role of GSTM1, GSTP1, and GSTT1 gene polymorphism in ifosfamide metabolism affecting neurotoxicity and nephrotoxicity in children","volume":"27","author":"Zieli\u0144ska","year":"2005","journal-title":"J Pediatr Hematol Oncol"}],"container-title":["Pharmacological Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003169972400721X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003169972400721X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/pharmrev.120.000121","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T17:40:09Z","timestamp":1740764409000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S003169972400721X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":341,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S003169972400721X"],"URL":"https:\/\/doi.org\/10.1124\/pharmrev.120.000121","relation":{},"ISSN":["0031-6997"],"issn-type":[{"value":"0031-6997","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Nitrogen Mustards","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/pharmrev.120.000121","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by The Author(s)","name":"copyright","label":"Copyright"}]}}